SynthesisBMC women's health2025
Mesenchymal stem cell therapy for endometrial injury: a meta-analysis of preclinical studies.
Synthesis in BMC women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundEndometrial injury is a common cause of menstrual changes, abortion, and even infertility in women, including intrauterine adhesions (Asherman’s syndrome) and a thin endometrium. Hysteroscopic surgery and drug treatment are currently the main treatment methods; however, their effect is not satisfactory. Increasingly, studies have demonstrated that mesenchymal stem cells (MSCs) may be a safe and promising option for treating endometrial injury. This study aimed to evaluate the efficacy of MSCs in an endometrial injury model.
methodsWe searched PubMed, Cochrane Library, Web of Science, and EMBASE from the establishment of the databases to December 2023. Preclinical studies examining the role of MSCs in treating endometrial injury were included. The main outcome measures were the endometrial thickness, fibrosis area ratio, and recovery of reproductive function. Risk of bias assessment was performed using the SYRCLE tool. RevMan 5.3 was used for the meta-analysis and testing heterogeneity.
resultsA total of 10 Randomized Controlled Trials (RCTs) involving 230 animals were included. The analysis showed that after treatment with MSCs, the endometrium was significantly thickened (WMD 115.01 μm, 95% CI (94.07–135.95 μm)), the area ratio of endometrial fibrosis reduced (WMD − 29.88, 95% CI (− 36.61–−23.15)), and the pregnancy rate increased (RR 4.60, 95% CI (2.09–10.13)). Subgroup analyses indicated that Human amniotic mesenchymal stem cells (HA-MSCs) seemed to be more effective than other types. In addition, we found that the treatment’s efficacy is also affected by the route of administration, the type of transplantation, and other factors.
conclusionsThe results of this study indicate that treatment with MSCs (HA-MSCs delivered via intrauterine injection) exerts beneficial effects on endometrial injury in rats.Xenogeneic MSCs showed enhanced therapeutic potential relative to allogeneic MSCs in our experimental models.Taken together, these data highlight MSCs as a potentially valuable approach warranting additional research for the treatment of endometrial injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.